As per the terms of the CRADA, Division of Cancer Treatment and Diagnosis (DCTD) of NCI intends to sponsor PCI-32765 Phase 1 and Phase 2 trials in certain hematologic malignancies, including multiple myeloma and non-Hodgkin lymphoma (NHL).
Pharmacyclics Oncology Development vice president Eric Hedrick said this CRADA represents a major achievement for the company, and allows them to broaden their knowledge of PCI-32765 based on clinical trials to be performed by leading investigators in the field of hematologic malignancies.